Arcadia Biosciences, Inc.

Arcadia Biosciences, Inc.

RKDA
Arcadia Biosciences, Inc.US flagNASDAQ Capital Market
0.65
USD
-0.02
- -
1.01MMarket Cap
Arcadia Biosciences, Inc.
RKDA
(NASDAQ Capital Market)

Recent

price

0.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
171.39
158.39
170.71
151.66
57.48
74.69
15.55
7.35
32.27
12.74
12.38
3.6
3.7
3.55
2.96
Revenue per Share
-302.44
-322.62
-539.78
-575.1
-353.85
-291.38
-143.16
-181.08
-18.7
-27.56
-25.65
-11.3
-5.16
-1.71
-5.81
Basic EPS, GAAP
-241.42
-240.71
-365.16
-427.47
-311.7
-260.53
-147.42
-117.4
-130.75
-50.52
-23.44
-12.37
-7.07
-3.46
-2.65
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2,015.55
-2,338.17
-2,786.55
-3,694.38
-2,731.91
-3,102.03
-1,893.81
-1,302.02
-850.57
-425.59
-430.09
-219.72
-204.51
-205.51
-177.83
Book Value per Share
-138.97
-422.91
-2,072.52
1,126.81
400.27
148.54
136.1
52.34
111.55
57.73
34.8
10.24
4.54
3
1.77
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
2
Basic Weighted Avg Shares
7
6
7
5
3
4
1
1
8
7
7
4
5
5
5
Sales/Revenue/Turnover
-144.51
-163.11
-217.03
-287.46
-584.07
-355.56
-1,152.32
-1,743.46
-268.76
-424.12
-205.28
-135.11
-150.88
-205.74
-200.78
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
- -
- -
- -
Depreciation Expense
-12
-13
-18
-18
-20
-16
-13
-29
-5
-15
-15
-14
-7
-2
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-176.46
-203.69
-262.66
-331.66
-615.56
-390.14
-920.77
-2,464.07
-57.94
-216.22
-207.28
-313.9
-139.5
-48.15
-195.94
Profit Margin (%)
5
-5
7
49
49
12
20
23
25
30
21
11
7
4
4
Working Capital
8
10
9
25
25
- -
- -
2
7
2
1
- -
- -
- -
- -
LT Debt
-6
-17
-85
40
22
8
13
8
29
31
21
13
6
4
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.83
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
2
Market Capitalization
5
3
2

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
8
6
5
Cash, Cash Equivalents & STI
6
5
4
Accounts Receivable, Net
1
- -
- -
Inventories
1
1
1
Total Current Liabilities
2
2
1
Payables & Accruals
2
2
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.18%
-29.49%
-33.47%
Free Cash Flow
-4.19%
-28.82%
-50.86%
Net Income, GAAP
9.93%
18.86%
-66.77%
Sales/Revenue/Turnover
45.2%
-7.32%
-3.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
2
1
5
2025
1
1
1
1
5
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.78
0.78
-1.18
- -
-5.16
2025
1.9
-3.26
0.63
- -
-1.71
2026
-2.11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Arcadia Biosciences, Inc. (Nasdaq: RKDA) produces and markets plant-based health and wellness products, including specialty crop ingredients and branded consumer goods, in the United States. The company develops advanced wheat improvements under the GoodWheat brand, offering high-fiber, reduced-gluten, high-protein, and low-calorie flours and ingredients with extended shelf life that enhance nutritional profiles and farm economics; Zola coconut water in original, pulp, espresso, lime, and pineapple flavors as a natural, low-calorie hydration product sourced from Thailand; and other wellness offerings such as ProVault topical pain relief and SoulSpring body care products. Founded in 2002 and headquartered in Dallas, Texas, Arcadia Biosciences operates primarily in the consumer staples sector, targeting food manufacturers, processors, and retail consumers with functional foods and beverages. In December 2024, the company entered a definitive all-stock business combination agreement with Roosevelt Resources LP, under which Arcadia will issue shares representing approximately 90% post-closing ownership to Roosevelt partners in exchange for its equity interests, shifting strategic focus toward oil and gas field development in the RR-Googins field while streamlining prior operations around Zola and GoodWheat.

Company News

APIChatGPT
  • Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  • Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  • Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  • Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  • Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights

  • Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights

  • Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds

  • Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources

  • Arcadia Biosciences (NASDAQ:RKDA) Shares Cross Below Fifty Day Moving Average – Here’s Why

  • Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

  • Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights

  • Arcadia Biosciences, Inc. (RKDA) Q1 2025 Earnings Call Transcript

  • Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

  • Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call

  • Arcadia Biosciences, Inc (RKDA) Q4 2024 Earnings Call Transcript

  • Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights

  • Arcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2024 Financial Results and Business Highlights Conference Call

  • RKDA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Arcadia Biosciences, Inc. is Fair to Shareholders

  • ARCADIA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Arcadia Biosciences, Inc. - RKDA

  • Arcadia Biosciences to Merge With Roosevelt, Shares Surge 105%